Skip to main content

JATT III Acquisition Corp Listed SPAC Primary

Proposed symbol JTTT on The Nasdaq Capital Market · First filed Aug 10, 2026 · CIK 2145659

Effective prospectus: 424B4 Aug 26, 2026 (0001213900-26-093949) · terms available

“This is an initial public offering of our ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00.”

Now trading as JTTT →

Offer price
$10
Shares offered
Not stated
Revenue (FY —)
Not available
Net income (FY —)
Not available

What the company does

JATT III Acquisition Corp is a blank check company incorporated as a Cayman Islands exempted company with limited liability. It was formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected a specific business combination target and has not engaged in substantive discussions with any target.

Use of proceeds

The company will hold $60,000,000 of the public offering proceeds in a trust account, subject to the terms described in the prospectus, and will use the approximately $1,100,000 not held in trust for business-combination expenses, target-business due diligence and research, regulatory-reporting fees, office space, utilities, administrative services, and remote support services.

Underwriters

The completed effective-prospectus read stated no underwriters.

Extracted from 424B4 0001213900-26-093949, filed Aug 26, 2026 and verified against that filing text.

Key risk factors

  • No selected business combination target
    “We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us.”
  • Inability to complete business combination
    “If we are unable to complete our initial business combination within the completion window, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (less taxes paid or payable (other than excise or similar taxes) and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law and certain limitations and on the conditions as further described herein.”
  • Potential investment-company status
    “To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer we hold investments in the trust account, we may, at any time, instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account uninvested in cash or in an interest-bearing or non-interest-bearing demand deposit account.”
  • Private-placement dilution risk
    “If we sell shares to AI Biotechnology or Vianti (or any other investor) in connection with our initial business combination, the equity interest of investors in this offering in the combined company may be diluted and the market prices for our securities may be adversely affected.”
  • Founder-share dilution
    “Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering.”

Financials before the first trade

The completed SEC companyfacts import produced no qualifying full-year financial history for this filer.

Filing history

Filed Form Accession
2026-08-26 424B4 0001213900-26-093949 View on EDGAR
2026-08-10 S-1 0001213900-26-086864 View on EDGAR

Source quotes

Offer price: “This is an initial public offering of our ordinary shares, par value $0.0001 per share, which we refer to as our public shares, at an initial public offering price of $10.00.”